6.09
price down icon5.58%   -0.36
after-market 시간 외 거래: 6.09
loading
전일 마감가:
$6.45
열려 있는:
$6.2
하루 거래량:
2.81M
Relative Volume:
2.99
시가총액:
$429.89M
수익:
$20.76M
순이익/손실:
$-132.49M
주가수익비율:
-2.1368
EPS:
-2.85
순현금흐름:
$-108.55M
1주 성능:
+3.22%
1개월 성능:
+13.20%
6개월 성능:
-9.64%
1년 성능:
+290.38%
1일 변동 폭
Value
$5.84
$6.3695
1주일 범위
Value
$5.2219
$6.52
52주 변동 폭
Value
$1.06
$11.88

C 4 Therapeutics Inc Stock (CCCC) Company Profile

Name
명칭
C 4 Therapeutics Inc
Name
전화
(617) 231-0700
Name
주소
490 ARSENAL WAY, WATERTOWN
Name
직원
145
Name
트위터
Name
다음 수익 날짜
2024-10-30
Name
최신 SEC 제출 서류
Name
CCCC's Discussions on Twitter

C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2023-02-24 업그레이드 Credit Suisse Underperform → Neutral
2023-02-24 다운그레이드 JP Morgan Neutral → Underweight
2022-11-04 다운그레이드 JP Morgan Overweight → Neutral
2022-10-11 개시 Morgan Stanley Underweight
2022-04-28 개시 Credit Suisse Underperform
2022-04-11 다운그레이드 BofA Securities Buy → Neutral
2022-03-10 개시 JP Morgan Overweight
2022-02-11 재개 BMO Capital Markets Outperform
2022-02-10 개시 Wells Fargo Equal Weight
2021-11-23 개시 BofA Securities Buy
2021-10-14 개시 SVB Leerink Mkt Perform
2021-09-30 개시 Stifel Hold
2021-06-04 개시 H.C. Wainwright Buy
2021-03-31 개시 BMO Capital Markets Outperform
2020-10-28 개시 UBS Buy
2020-10-27 개시 BMO Capital Markets Outperform
2020-10-27 개시 Jefferies Buy
모두보기

C 4 Therapeutics Inc 주식(CCCC)의 최신 뉴스

pulisher
04:25 AM

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

04:25 AM
pulisher
04:01 AM

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

04:01 AM
pulisher
09:11 AM

C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin's Lymphoma at the American Society of Hematology (ASH) Annual Meeting - The Manila Times

09:11 AM
pulisher
09:00 AM

C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin's Lymphoma At the American Society of Hematology Annual Meeting - Marketscreener.com

09:00 AM
pulisher
07:02 AM

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

07:02 AM
pulisher
06:30 AM

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

06:30 AM
pulisher
Nov 04, 2024

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Nov 04, 2024
pulisher
Nov 04, 2024

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Nov 04, 2024
pulisher
Nov 01, 2024

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Nov 01, 2024
pulisher
Nov 01, 2024

ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 01, 2024
pulisher
Nov 01, 2024

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 01, 2024
pulisher
Nov 01, 2024

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Marketscreener.com

Nov 01, 2024
pulisher
Nov 01, 2024

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Kilgore News Herald

Nov 01, 2024
pulisher
Nov 01, 2024

C4 Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 01, 2024
pulisher
Nov 01, 2024

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 01, 2024
pulisher
Nov 01, 2024

C4 Therapeutics Advances in Protein Degradation Therapy - TipRanks

Nov 01, 2024
pulisher
Oct 31, 2024

C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Tops Revenue Estimates - MSN

Oct 31, 2024
pulisher
Oct 31, 2024

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Oct 31, 2024
pulisher
Oct 31, 2024

C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - The Manila Times

Oct 31, 2024
pulisher
Oct 31, 2024

C4 Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Oct 31, 2024
pulisher
Oct 31, 2024

C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

Oct 31, 2024
pulisher
Oct 29, 2024

We're Hopeful That C4 Therapeutics (NASDAQ:CCCC) Will Use Its Cash Wisely - Yahoo Finance

Oct 29, 2024
pulisher
Oct 28, 2024

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Oct 28, 2024
pulisher
Oct 26, 2024

C4 Therapeutics, Inc. (NASDAQ:CCCC) Short Interest Update - MarketBeat

Oct 26, 2024
pulisher
Oct 25, 2024

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Citizentribune

Oct 25, 2024
pulisher
Oct 17, 2024

C4 Therapeutics appoints Paige Mahaney as new CSO - Investing.com India

Oct 17, 2024
pulisher
Oct 16, 2024

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Oct 16, 2024
pulisher
Oct 16, 2024

C4 Therapeutics appoints Paige Mahaney as new CSO By Investing.com - Investing.com Canada

Oct 16, 2024
pulisher
Oct 15, 2024

C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer - citybiz

Oct 15, 2024
pulisher
Oct 15, 2024

C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief - GlobeNewswire

Oct 15, 2024
pulisher
Oct 15, 2024

C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D. - StockTitan

Oct 15, 2024
pulisher
Oct 15, 2024

How should investors view C4 Therapeutics Inc (CCCC)? - US Post News

Oct 15, 2024
pulisher
Oct 15, 2024

C4 Therapeutics Inc: Navigating Market Fluctuations with a 407.72M Market Cap - The InvestChronicle

Oct 15, 2024
pulisher
Oct 14, 2024

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Business Wire

Oct 14, 2024
pulisher
Oct 14, 2024

Financial Metrics Exploration: Understanding C4 Therapeutics Inc (CCCC) Through Ratios - The Dwinnex

Oct 14, 2024
pulisher
Oct 14, 2024

C4 Therapeutics amends incentive plan, barring repricing without shareholder nod - Investing.com

Oct 14, 2024
pulisher
Oct 14, 2024

C4 Therapeutics amends incentive plan, barring repricing without shareholder nod By Investing.com - Investing.com South Africa

Oct 14, 2024
pulisher
Oct 12, 2024

Squarepoint Ops LLC Has $264,000 Holdings in C4 Therapeutics, Inc. (NASDAQ:CCCC) - Defense World

Oct 12, 2024
pulisher
Oct 12, 2024

Cubist Systematic Strategies LLC Has $2.59 Million Stake in C4 Therapeutics, Inc. (NASDAQ:CCCC) - MarketBeat

Oct 12, 2024
pulisher
Oct 11, 2024

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Oct 11, 2024
pulisher
Oct 11, 2024

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Oct 11, 2024
pulisher
Oct 10, 2024

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Oct 10, 2024
pulisher
Oct 10, 2024

Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Oct 10, 2024
pulisher
Oct 09, 2024

C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit - The Manila Times

Oct 09, 2024
pulisher
Oct 08, 2024

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Oct 08, 2024
pulisher
Oct 08, 2024

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire

Oct 08, 2024
pulisher
Oct 07, 2024

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) - Yahoo Finance

Oct 07, 2024
pulisher
Oct 07, 2024

Renaissance Technologies LLC Has $1.09 Million Stake in C4 Therapeutics, Inc. (NASDAQ:CCCC) - MarketBeat

Oct 07, 2024
pulisher
Oct 06, 2024

C4 Therapeutics, Inc. (NASDAQ:CCCC) Given Average Rating of "Hold" by Brokerages - MarketBeat

Oct 06, 2024
pulisher
Oct 04, 2024

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Oct 04, 2024
pulisher
Oct 04, 2024

Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - GlobeNewswire

Oct 04, 2024

C 4 Therapeutics Inc (CCCC) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
자본화:     |  볼륨(24시간):